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Abstract
Laminopathy is a disease closely related to deficiency of the nuclear matrix protein lamin A/C or failure in prelamin
A processing, and leads to accumulation of the misfold protein causing progeria. The resultant disrupted lamin
function is highly associated with abnormal nuclear architecture, cell senescence, apoptosis, and unstable genome
integrity. To date, the effects of loss in nuclear integrity on the susceptible organ, striated muscle, have been
commonly associated with muscular dystrophy, dilated cardiac myopathy (DCM), and conduction defeats, but have
not been studied intensively. In this review, we aim to summarize recent breakthroughs in an in vivo laminopathy
model and in vitro study using patient-specific human induced pluripotent stem cells (iPSCs) that reproduce the
pathophysiological phenotype for further drug screening. We describe several in-vivo transgenic mouse models
to elucidate the effects of Lmna H222P, N195K mutations, and LMNA knockout on cardiac function, in terms of
hemodynamic and electrical signal propagation; certain strategies targeted on stress-related MAPK are mentioned. We
will also discuss human iPSC cardiomyocytes serving as a platform to reveal the underlying mechanisms, such as the
altered mechanical sensation in electrical coupling of the heart conduction system and ion channel alternation in
relation to altered nuclear architecture, and furthermore to enable screening of drugs that can attenuate this cardiac
premature aging phenotype by inhibition of prelamin misfolding and oxidative stress, and also enhancement of
autophagy protein clearance and cardiac-protective microRNA.
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Background
The LMNA gene locates in the long branch of chromo-
some 1, producing two main isoforms by alternative
splicing (i.e., lamin A and C). These isoforms are the
intermediate filaments and constitute the major com-
ponents of the nuclear lamina [1]. Lamin A and C are
present in most somatic cells that have a multimeric
fibrous structure surrounding the nucleus and provide
support to the nuclear membrane proteins. In recent
years, the role of lamin A/C has been investigated, for
example, in the maintenance of chromatin organization
during cell division, signal transduction, differentiation
maintenance, repair, and anchoring of other lamin-
binding proteins, such as emerins, desmin, and nesprin.
Mutations in LMNA have been shown to cause a wide
range of human diseases, collectively referred to as
“laminopathies” [2–4]. These include Hutchinson Gilford
progeria syndrome (HGPS, premature aging syndrome)
caused by a truncated splicing mutation of the LMNA
gene, resulting in the generation of progerin, muscular
dystrophy, and familial dilated cardiomyopathy (DCM).
The mutations may also affect muscle, fat, bone, nerve,
and skin tissues and lead to inherited neuromuscular
disease with multiple phenotypic expressions such as
Emery–Dreifuss muscular dystrophy (EDMD), limb
girdle muscular dystrophy 1B (LGMD1B), Dunnigan-
type familial partial lipodystrophy, a recessive axonal
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form of Charcot–Marie–Tooth neuropathy, and mandi-
buloacral dysplasia. However, there is a lack of under-
standing about the underlying mechanisms concerning
lamin insufficiency or misfolding of such protein in car-
diac disease progression. Current existing platforms for
cardiolaminopathy modeling rely on transgenic mice to
determine gene dose effects of the heterogeneous and
homogeneous mutation system, the animal replicated
clinical phenotypes with muscle dystrophy, premature
DCM syndromes, as well as atrioventricular (AV) block.
Although rodent systems allow studies of whole heart
function, the cardiac physiological makeup is deviated
from the human condition. Recent breakthroughs in
generation of human induced pluripotent stem cell
(iPSC) technologies allow access to patient-specific ma-
terials (e.g., heart, gut, neurons, and liver cells) that
recapitulate the disease phenotype in a culture system.
Recently, scientists have relied on such a system for
electrophysiological study at a single cell level, as a plat-
form to determine deterioration of nuclear architecture
due to premature cell senescence, and also to determine
energy synthesis dynamics. More importantly, the human
cardiac cell would allow pilot drug-screening studies on
targeting oxidative stress signaling in cardiac laminopathy,
clearance of misfolded lamin proteins, delay in the rate of
producing toxic farnesylated lamin, arising from mutation
at cleavage sites of prelamin A/C protein, the blockade
of stress-related MEK1–Erk1/2, JNK, and p38-mediated
MAPK pathways, or even the cardiac protective micro-
RNA (miR) that reduces prelamin A accumulation.
More recently, the breakthroughs in gene editing tech-
nologies allow allogeneic cell therapies or generation of
isogenic control. The use of iPSC derivatives could be
used as a critical and powerful tool for standardized
and comparative pharmacological studies.
Clinical observations in cardiac laminopathy
Various genetic causes have been identified that play a
vital role in the formation of DCM, although in most cases
the underlying mechanism remains unknown. More
than 60 genes have been identified, including the lamin
A/C gene (LMNA), that cause monogenic DCM [5].
LMNA-related DCM is characterized by early onset of
atrial fibrillation, conduction system disease, and subse-
quent progression to sudden cardiac death and prema-
ture heart failure [6–9]. To date, 20 % of gene mutations
associated with DCM are believed to be linked to Titin
(TTN). LMNA mutations are the second most common
cause of familial DCM, responsible for 5–10 % of overall
familial DCM and up to 30–45 % of families with DCM
and conduction system disease [10, 11]. Although the age
at presentation of LMNA-related DCM ranges from the
first to sixth decade of life, the laminopathy-mediated car-
diac defeats are always progressive and almost all patients
become symptomatic after age 60 [7, 8, 12]. Furthermore,
LMNA-related DCM, especially that associated with con-
ductive system diseases, has a more malignant clinical
course than other familial DCM because of the high rates
of progressive heart failure and sudden cardiac death due
to ventricular tachyarrhythmias, and the ultimate treat-
ment would rely on heart transplantation [12–15]. Despite
our increasing awareness of the importance of LMNA-
related DCM, the mechanisms of the disease as well as
therapeutic strategies to prevent its onset and progres-
sion remain unclear. Early clinical manifestations are
often apparent in the conduction system and specifically
lead to sick sinus syndrome, and AV block or bundle
branch block with approximately 28 % of affected patients
requiring permanent pacemaker implantation [16, 17].
A meta-analysis of 299 patients with an LMNA gene
mutation suggested that cardiomyopathy due to LMNA
mutations indicates a high probability of sudden death
[17]. The analysis revealed that 92 % of patients over
the age of 30 years suffered cardiac arrhythmias, 64 %
after age 50 years suffered heart failure, and both the
cardiac and neuromuscular phenotype was reported in
46 % of cases of sudden death. A pacemaker was
implanted in 28 % of lamin A/C gene mutation carriers,
although this did not alter the rate of sudden death.
More recently, Andre et al.’s study described a LMNA
T655fsX49 mutation that led to lipodystrophic laminopa-
thy. In fact, the mutation was associated with failure in
processing of prelamin A which resulted in accumulation
of nonfarnesylated mutated prelamin A. It was further
shown that there is a relationship between mutated prela-
min A accumulation and the severity of the phenotypes in
homozygous familial partial lipodystrophy type 2 patients
who harbor the LMNAT655fsX49 mutation [18] (Table 1).
Animal models of cardiac laminopathy
To provide initial insight into the pathophysiology of
LMNA-mediated DCM and muscular dystrophy, several
transgenic animal models of LMNA mutations have
been generated [19–21]. Either LMNA mutation knockin
(KI) (dominant negative) [20] or LMNA knockout (KO)
(haploinsufficiency) transgene presented apart from DCM
phenotypes [19, 21], but also variable phenotypes of the
conduction system disease (Table 1). In 2003, the first KO
mouse model of A-type lamin (Lmna−/−) was estab-
lished by Sullivan and colleagues [22, 23]. In early age,
these homozygous KO mice rapidly displayed a re-
tarded growth rate, which agreed with the phenotypes
presented in HGPS. Subsequently, all homozygous mice
died by the fourth week after birth. Apart from the sup-
pressed level of lmna, Bonne and colleagues introduced
an H222P mutation in LMNA in a mouse model, which
displayed typical cardiac conduction defects, chamber
dilation, and increased fibrosis but showed a lack of
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hypertrophy [24]. In fact, the Lmna-H222P mice also
showed signs of muscular dystrophy and underwent
premature death at 4–9 months for males and at 7–13
months for females. With the confirmation of pheno-
types resembling a patient’s condition, this model was
employed as a platform for drug screening of which
drugs act on stress-related pathways. Apart from the
H222P mutation, the group of Leslie and Serguei ob-
served the phenotype of homozygous KI-Lmna N195K
mice [25] that recapitulated the phenotype of DCM and
conduction system disease. The homozygous N195K
mice showed early signs of DCM, increased interstitial
fibrosis, irregular heart rhythm, and conduction defects,
with a high mortality rate at 6–8 months. The mutant
mice were observed to have sarcomeric and desmin
disorganization, mislocalization of connexin 43, and de-
creased expression of connexin 40. Although the mutation
suppressed lamin A/C expression, which was properly
localized at the nuclear envelope, the emerin connecting
intermediate filament with lamin A/C is partially mislo-
calized to the cytoplasm [26, 27].
In 2011, Kubben et al. [28] developed a novel LMNA
null mouse (LMNA GT–/–) by inserting a promoter in
intron 2 of LMNA, resulting in a LMNA-β-geo fusion
allele. This model combined the LMNA gene KO with
LMNA-driven reporter, and thus enabled in-vivo study
of the effect of conditional lamin A/C ablations during
early postnatal development. In these KO mice, hindered
growth, postnatal cardiomyocyte hypertrophy, skeletal
muscle dystrophy, and metabolic defects were observed
in the first 2 weeks after birth. Premature fatal events
were commonly observed in mice before weaning. Similar
results were later observed in a conditional LMNA KO
mouse model created by Kim and Zheng [29], with the
introduction of LoxP sites flanking the LMNA exon 2,
which were further crossed with CMV-Cre mice to create
a conditional KO driven by LMNA expression. The gener-
ated LMNA–/– mice exhibited growth delay from the first
12 days and died between postnatal days 16 and 18. It was
also suggested that loss of function in muscle was due to
the decreased skeletal myofibril size, similar to observa-
tions in Lmna GT−/− mice [28]. Overall, lamin A/C loss
may strongly affect the transcription of genes related to
muscle differentiation and thus account for the delayed
muscle maturation observed in various Lmna KO mouse
models (Fig. 1a).
Development of a potential therapeutic
intervention using a transgenic animal model
Despite our increasing awareness of the importance of
LMNA-related DCM, the mechanism of the disease as
well as therapeutic strategies to prevent its onset and
progression remain unclear. DCM with Lmna mutation
is always very aggressive. Common clinical manifesta-
tions are related to development of heart failure and
sudden cardiac death, for which ultimate treatment/pre-
vention relies on cardiac transplantation [30]. Although
conventional pharmacotherapy relies on angiotensin-
converting enzyme inhibitors (ACEI), there is no specific
treatment for the progressive loss of contractility in
LMNA-related cardiomyopathy. A mechanistic under-
standing of the physiopathological basis of such disease
is necessary to develop more specific and efficacious
therapeutic strategies.
In recent decades, the incidence of fatal tachyarrhythmia
has been greatly reduced by prophylactic implantation of
a cardioverter defibrillator [13]. Anselme et al. [31] re-
ported that the high incidence of life-threatening tachyar-
rhythmia in patients with LMNA mutation necessitated
implantation of a cardioverter defibrillator instead of a
pacemaker. In 2007, in order to investigate the pathogene-
sis of LMNA cardiomyopathy, Muchir et al. implemented
Table 1 Phenotype of the mutated LMNA mouse model and the human iPSC model
Model LMNA mutation Phenotype Reference
Animal Knockout Retarded growth rate and early death [26]
Conditional knockout Hindered growth; postnatal cardiomyocyte hypertrophy,
skeletal muscle dystrophy
[28, 29]
H222P Cardiac conduction defeats, chamber dilation and enhanced
incidence of fibrosis; muscular dystrophy
[20, 24, 52, 53]
N195K DCM and conduction system disease; irregular heart rhythm [25]
Human HGPS Epigenetic alternation associated with premature aging;
vascular aging; premature osteogenesis
[42, 44, 45, 48]
T655fsX49 Lipodystrophy type 2; muscle hypertrophy; Atrial fibrillation (AF); cardiac
conduction disease with first-degree AV block and homozygous patients
showed frequent secondary-degree AV block; DCM; ventricular arrhythmia
[18]
R225X Patients showed early onset of AF, secondary AV block and DCM;
retarded human iPSC-derived cell proliferation, premature cell
senescence; viability of CMCs susceptible to stress condition
(e.g. electrical field stimulation)
[6, 52, 54–56]
AV atrioventricular, CMC cardiomyocyte, DCM dilated cardiomyopathy, HGPS Hutchinson Gilford progeria syndrome, iPSC induced pluripotent stem cell
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a genome-wide transcriptome analysis of hearts isolated
from Lmna H222P mice. Significant differences were
noted in the expression of gene encoding proteins in
stress-activated MAPK and mTOR signaling pathways in
the mutated mice. Their work clearly verified an abnormal
increase in both MAPK and mTOR activity in heart
tissue from Lmna H222P mice [20]. These results indi-
cated that MAPK and mTOR inhibition may offer an
alternative therapeutic option to delay the onset of
heart failure in LMNA-related cardiomyopathy. To de-
termine treatment for mutated LMNA-induced cardiac
disorders, Muchir et al. also treated Lmna H222P mice
with daily intraperitoneal injections of the MEK1/2
inhibitor (Selumetinib). Selumetinib treatment resulted
in left ventricular (LV) end-systolic dilatation, increased
ejection fraction, and blocked molecular cardiac re-
modeling (i.e., blocked increased cardiac natriuretic fac-
tor transcripts and halted the induction of elements of
a
b
Fig. 1 a Schematic diagram of existing laminopathy animal modeling and the phenotypes. b Development of pharmacological treatment
on targeted pathways affected by laminopathy. HGPS Hutchinson Gilford progeria syndrome, MAPK mitogen-activated protein kinase,
MEK1 MAPK–extracellular signal-regulated kinase-1
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the “fetal gene program”), with consequent improved
cardiac function compared with placebo-treated mice.
Since cardiac fibrosis is a common manifestation in end-
stage DCM, and particularly in LMNA cardiomyopathy,
cardiac fibrosis was also examined in this experiment. The
Selumetinib-treated group had a lower degree of cardiac
fibrosis than the placebo group. The same research group
also revealed that germline deletion of ERK1 in the same
mutant mice resulted in enhanced heart function at an
early age (16 weeks old) [32], although the improvement
could not be sustained beyond 20 weeks of age. ERK2
has also been strongly activated by more than two-fold
in Lmna H222P mice. After cardiac ERK2 activity was
blocked with Selumetinib, the ejection fraction at 20 weeks
was significantly enhanced, implying that the increased
ERK2 activity compensated for the ERK1 ablation and re-
sulted in deteriorated heart function in the Lmna H222P
mice that lacked ERK1 activity. They also found that
inhibiting JNK (SP600125) [33, 34] or p38 (ARRY797)
exerted beneficial effects on LV dysfunction in the
mice. In addition to the enhanced ERK1/2 signaling, ac-
tivities of the other stress response MAPKs, JNK and
p38, were also enhanced at an early stage of disease in
Lmna H222P mice hearts [20, 35]. Therefore, p38 and
JNK activity increased in Lmna H222P/Erk1 null mice
compared with control LMNA-WT/Erk1 null mice when
LV function started to change. We have previously re-
ported the benefits of inhibiting JNK (SP600125) [33, 34]
or p38 (ARRY797) in LV dysfunction in LmnaH222P
mice. In future experiments, a combination of inhibitors
of p38 and JNK in LmnaH222P/Erk1null mice may be
used to identify their effect on heart function and may
help clarify the individual or overlapping functions of
these diverse signaling pathways in heart pathology
affected by the LMNA mutation.
After the experiment with MAPK inhibitors, Muchir’s
team treated the Lmna H222P mice for 2 weeks with a
mTOR inhibitor, Temsirolimu, for clearance of waste
protein generated by autophagy [36]. Similar to the re-
sults of Selumetinib treatment, improved heart function
of the treated mice presented with enhanced LV end-
systolic dilation and ejection fraction and attenuated car-
diac remodeling (Fig. 1b).
Human induced pluripotent stem cell modeling of
laminopathy and drug screening
The high mortality of these LMNA knockout mice re-
stricted the possibility of chronic whole animal study.
In addition, differences in cardiac electrophysiological
behavior between humans and rodents may hinder the
feasibility of translating pathophysiological discoveries
into clinical practice. The mechanisms by which differ-
ent LMNA mutations cause AV block or DCM remain
uncertain. An in-vitro platform of human cardiomyocytes
derived from patients with different LMNA mutations
would be extremely useful for understanding disease
mechanisms under stress conditions such as electrical
field stimulation and mechanical stretch, as well as a
hypoxic environment, and hence developing patient-
specific therapies.
The recent breakthrough of human iPSCs generated
from adult somatic tissues [37, 38] provides a unique op-
portunity to produce patient-specific cardiomyocytes for
disease modeling and drug screening [39–41] (Table 1
and Fig. 2). Since iPSCs are genetically identical to the
host bearing cardiac defeats, the iPSC-derived cardio-
myoctes provide an attractive experimental platform to
recapitulate cellular phenotypes of familial heart diseases
such as arrhythmias and cardiomyopathies. This will pro-
vide new insights into disease-modifying mechanisms and
enable the specific design of personalized therapeutic
strategies.
In 2011, Liu et al. [42] began to use human iPSCs for
HGPS modeling. HGPS is caused by a single point mu-
tation in the lamin A (LMNA) gene, resulting in the
generation of progerin, a truncated splicing mutant of
lamin A. The level of progerin accumulates with ages
and leads to various ageing-associated nuclear defects
including disorganization of the nuclear lamina and loss
of heterochromatin. The reversible suppression of pro-
gerin expression by reprogramming was resumed upon
differentiation with ageing-associated phenotypic conse-
quences. The HGPS-iPSCs derived from skin fibroblasts
showed an absence of progerin and more importantly
lacked the nuclear envelope and epigenetic alterations
normally associated with premature ageing. Nevertheless,
the appearance of premature senescence phenotypes in
HGPS-iPSC-derived smooth muscle cells (SMCs) was
associated with vascular ageing. Additionally, they identi-
fied a DNA-dependent protein kinase catalytic subunit
(DNAPKcs, also known as PRKDC) as a downstream
target of progerin. The absence of nuclear DNAPK holo-
enzyme correlated with premature as well as physiological
ageing. Others have reported the use of a human iPSC
platform to model the disease phenotypes of HGPS in
mesenchymal lineages and SMCs [42, 43]. Ho et al. as well
as Liu et al. generated progeria iPSCs from skin fibroblasts
of a patient bearing a mutation in LMNA [42, 44]. They
proved that the human iPSC-derived fibroblasts are able
to recapitulate the disease phenotype with prominent
nuclear blebbing, are capable of cell senescence, and are
susceptible to external stimulation (e.g., electrical field
stimulation as the donor cells). Liu et al. showed that pre-
mature vascular ageing was probably due to accumulation
of progerin in SMCs. Later, Blondel et al. in 2014 further
investigated the translational aspect using iPSCs to reveal
functional differences between drugs currently investigated
in patients with HGPS. They trialed a farnesyltransferase
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inhibitor in combination with a statin (zoledronate and
pravastatin), and the macrolide antibiotic rapamycin. This
study revealed that a systematic cytostatic effect was ob-
served in the treatment group with the farnesyltransferase
inhibitor alone [45]. The investigators provide new insights
into drug efficacy in functional improvement of prelamin A
farnesylation that generates cytotoxic progerin, nuclear
architecture, improvement in cell proliferation, as well as
energy metabolism; in other words, ATP synthesis. This
finding further proved iPSCs to be powerful tools for stan-
dardized and comparative pharmacological studies.
In 2012, our group subsequently generated another
human iPSC platform from a patient bearing a premature
termination codon in the LMNA gene, R225X. Although
no clear nuclear phenotype was observed in iPSCs from
the DCM patient with the LMNA mutation, several
cellular phenotypes were observed in the human iPSC-
derived cardiomyocytes, including nuclear morphology
abnormality (blebbing), slow proliferation, improved
cellular senescence, and increased incidence of
apoptosis under electrical stimulation. Under field elec-
trical stimulation to mimic the native cardiac environ-
ment, the percentage of LMNA‐mutated iPSC
cardiomyocytes that exhibited nuclear senescence and cel-
lular apoptosis markedly increased. shRNA knockdown of
LMNA, resembling the halploinsufficiency situation of the
R225X mutant, replicated those phenotypes of the mu-
tated LMNA field electrical stress. We also demonstrated
the central role of the MAPK–extracellular signal-
regulated kinase-1 (MEK1) pathway in governing suscepti-
bility to cardiac cell stress-response. Blockage of the extra-
cellular signal-regulated kinase (ERK) pathway by MEK1
inhibitors attenuated the electrical stimulation-induced
proapoptotic phenotypes of DCM iPSC cardiomyocytes
[6]. ERK1/2 are activated directly by the upstream MEK1/
2, which are dual-specificity protein kinases. Activated
ERK1/2 kinases phosphorylate and activate a variety of
substrates, which can be transcription factors, protein ki-
nases and phosphatases, cytoskeletal and scaffold proteins,
receptors and signaling molecules, and apoptosis-related
Fig. 2 Schematic summary of existing cardiac laminopathy human iPSC modeling and future studies to understand the disease mechanism, drug
screening, and interventions. HGPS Hutchinson Gilford progeria syndrome, miR microRNA, MLK Mixed-lineage kinases. [57, 58]
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proteins. Numerous MEK1/2 inhibitors have progressed
into clinical trials since the identification of the first MEK
inhibitor, PD098059 [46]. Most of these MEK1/2 inhibi-
tors are ATP noncompetitive and bind to a unique allo-
steric site adjacent to the ATP site. Apart from
pharmacological treatment of LMNA mutation-related
disease, there were new breakthroughs in gene editing
technologies for correction of laminopathy-associated
LMNA mutations in patient-specific iPSCs. However, Liu
et al. [42] discovered that the LMNA gene was transcrip-
tionally inactive and would impede targeted gene editing.
They further explored using helper-dependent adeno-
viral vectors (HDAdVs) as a robust and highly efficient
vehicle for the delivery of gene editing tools. In com-
parison with the conventional piggybac method, the
advantage of this system is the inclusion of a negative
selection step by ganciclovir (GNAC) resistance to elim-
inate random insertion of clones that contain the HSVtk
cassette. The resultant corrected HPGS iPSCs were
essentially proved to be genetically identical to fibro-
blasts as well as epigenetically similar to the uncor-
rected clones. Such a new method would enhance the
reliability of gene correction as a therapeutic tool to
rescue the disease phenotype for cell therapies or to
generate a patient-matched control for disease model-
ing and further the dissected disease causal target for
drug discovery [47].
In fact, somatic reprogramming of the progeria patient-
specific cell to a human iPSC is not an easy task with the
considerable drawback of low efficiency of stem cell clone
formation. The stress of premature aged cells was basically
due to oxidative stress-related NF-kB activation, which
blocks the generation of iPSCs and MSC differentiation.
Soria-Valles et al. discovered that NF-kB repression oc-
curred during reprogramming towards a pluripotent state.
In contrast, the hyperactivation of NF-kB impaired the
process though DOT1L, a histone H3 methyltransferase,
which reinforced the senescence signals [48]. In the
light of such observations, the authors demonstrated at-
tenuating the NF-kB signal via direct or upstream DOT1L
inhibition before somatic reprogramming, which also ex-
tended the lifespan and ameliorated the accelerated ageing
phenotype in the animal model. Chronic treatment of NF-
kB inhibition, an anti-inflammatory compound, may pro-
duce side effects. Besides, DOT1L inhibitors have recently
been tested for the treatment of hematological malignan-
cies, which suggests a better solution for age-associated
diseases [49].
Apart from epigenetic profiling, the tissue-specific ex-
pression profile of miR may provide clues for laminopathy
therapies. miR-9 was specifically expressed in neuronal
cells derived from HGPS patients, which exerted a pro-
tective role of the miR specifically to preserve cognitive
function [50]. The miR-9 acting 3′-untranslated region
(UTR) of lamin A suppresses its expression level, thus
reducing accumulation of prelamin A, which generates
progerin. The direct role of miR-9 on lamin A gene ex-
pression was further confirmed by anti-miR-9 treat-
ment (loss of function) or transfection with pre-miR-9
(gain of function) in the HGPS iPSC-MSC. Future
studies on cardiac-specific laminopathy intervention could
be focus on inhibiting miR-9 or other cardiac-specific miR
targeting on the 3′-UTR of LMNA.
Conclusions and further studies
Different types of mutations in LMNA present varying
severity of cardiac laminopathy phenotypes, such as
alternation in splice variant maturation causing progerin
accumulation and haploid insufficiency. The mutations
could cause familial cardiomyopathy, early onset of AV
block, and lethal ventricular tachycardia. The findings of
translational implication facilitate screening of LMNA
mutation which might be beneficial for risk stratification
and clinical management of this type of familial cardio-
myopathy or arrhythmia. Further studies concerning the
effects of different lengths of truncated lamin proteins,
such as location in proximity to the prelamin A cleavage
site, need to be revealed. The overexpression of the
unstable form of truncated proteins would generate an
artificial system to extrapolate their prominent role in
disease progression or the severe disease phenotype was
only based on a reduced level of full-length Lmna. In an
animal model, cardiac laminopathy has been found to be
closely related to heart block, atrial fibrillation, and DCM.
The transgenic animal would allow cardiac hemodynamic
functional study and pharmacological testing. However,
the direct role of a specific mutation in presentation of
different forms of arrhythmia remains unknown. Further
in-depth investigation in the human cell environment
concerning the role of lamin in ion channel trafficking
and the contribution of tight junction protein (e.g., CX40
and CX43) in the conduction system to the cell con-
ductance would be necessary. Up to now, it is clear that
cardiac defeat mediated by LMNA mutation could be
ameliorated by manipulation of the Akt/mTOR path-
way by facilitating clearance of accumulated mutant
protein through the process of autophagy and MEK1-
mediated Erk1/2 by inhibition of apoptotic stress res-
ponses. As a consequence, further studies would also
rely on a human iPSC model to investigate more clinical
relevant outcomes. It would be interesting to explore
cardiac-specific presentation of a laminopathy pheno-
type based on mechanical sensitivity of nuclear lamins
coupled to membrane surface receptors.
In the new era of advances in epigenetic studies, we
could use a bioinformatics algorithm as a mathematical
model to predict the age of human tissues based on pro-
files of cytosine-5 methylation within CpG dinucleotides,
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also known as DNA methylation (DNAm). The use of
such an epigenetic clock based on 353 CpG sites could
be validated in multiple tissues to predict the research
gap in premature aging studies. It is well known that
age-related DNA hypomethylation has long been ob-
served in rodents [51]. The authors pointed out an im-
portant issue for iPSC modeling of premature aging
disease since the stem cells tend to have their DNAm
age reset to zero compared with the corresponding
somatic cells. They suggested performing multiple cell
passaging to accelerate the DNAm age that resembles
the actual situation. Indeed, the DNAm profile is not
only age specific, but also tissue type specific; one should
calibrate to a specific target type profile before inter-
pretation. Given the high heritability of age acceleration
in young subjects, iPSCs could be a powerful model to
study ageing dynamics in terms of genomic stability to
maintain DNAm in cardiac laminopathy from embryonic
to adult stages. In the future, DNAm age may become a
powerful surrogate marker for evaluating rejuvenation
therapies for drug screening in progeria or laminopathy
diseases.
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